Stay updated on Efgartigimod Safety & Efficacy in pSS Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod Safety & Efficacy in pSS Clinical Trial page.

Latest updates to the Efgartigimod Safety & Efficacy in pSS Clinical Trial page
- Check6 days agoChange DetectedThe page now displays Revision: v3.4.3 in the footer, replacing Revision: v3.4.2.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2, representing a minor update with no impact on study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check35 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1; this is a metadata/version control change and does not modify study content or user-facing information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedAdded a glossary display and a new QC-related metadata label (Last Update Submitted that Met QC Criteria) with a revision reference (v3.4.0), and adjusted capitalization of No FEAR Act data across the page.SummaryDifference0.2%

- Check57 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4, and this change does not modify study content, eligibility criteria, locations, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check78 days agoChange DetectedRevision: v3.3.3 has been added and the previous v3.3.2 entry along with the HHS Vulnerability Disclosure text were removed. No study details or content were changed.SummaryDifference0.1%

Stay in the know with updates to Efgartigimod Safety & Efficacy in pSS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod Safety & Efficacy in pSS Clinical Trial page.